-
1
-
-
77953707790
-
Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD
-
10.1136/thx.2009.125435, 20522841
-
Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, Bleasdale P, Owen R, Higgins M, Kramer B. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 2010, 65:473-479. 10.1136/thx.2009.125435, 20522841.
-
(2010)
Thorax
, vol.65
, pp. 473-479
-
-
Dahl, R.1
Chung, K.F.2
Buhl, R.3
Magnussen, H.4
Nonikov, V.5
Jack, D.6
Bleasdale, P.7
Owen, R.8
Higgins, M.9
Kramer, B.10
-
2
-
-
77954800883
-
Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium
-
10.1164/rccm.200910-1500OC, 20463178
-
Donohue JF, Fogarty C, Lotvall J, Mahler DA, Worth H, Yorgancioglu A, Iqbal A, Swales J, Owen R, Higgins M, Kramer B. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010, 182:155-162. 10.1164/rccm.200910-1500OC, 20463178.
-
(2010)
Am J Respir Crit Care Med
, vol.182
, pp. 155-162
-
-
Donohue, J.F.1
Fogarty, C.2
Lotvall, J.3
Mahler, D.A.4
Worth, H.5
Yorgancioglu, A.6
Iqbal, A.7
Swales, J.8
Owen, R.9
Higgins, M.10
Kramer, B.11
-
3
-
-
77951221549
-
Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study
-
10.1186/1471-2466-10-11, 2848004, 20211002
-
Feldman G, Siler T, Prasad N, Jack D, Piggott S, Owen R, Higgins M, Kramer B. Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med 2010, 10:11. 10.1186/1471-2466-10-11, 2848004, 20211002.
-
(2010)
BMC Pulm Med
, vol.10
, pp. 11
-
-
Feldman, G.1
Siler, T.2
Prasad, N.3
Jack, D.4
Piggott, S.5
Owen, R.6
Higgins, M.7
Kramer, B.8
-
4
-
-
79953026850
-
Once-daily indacaterol vs twice-daily salmeterol for COPD: a placebo-controlled comparison
-
Kornmann O, Dahl R, Centanni S, Dogra A, Owen R, Lassen C, Kramer B. Once-daily indacaterol vs twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J 2010, 37:273-279.
-
(2010)
Eur Respir J
, vol.37
, pp. 273-279
-
-
Kornmann, O.1
Dahl, R.2
Centanni, S.3
Dogra, A.4
Owen, R.5
Lassen, C.6
Kramer, B.7
-
5
-
-
77950340063
-
Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design
-
10.1016/j.pupt.2010.01.003, 20080201
-
Barnes PJ, Pocock SJ, Magnussen H, Iqbal A, Kramer B, Higgins M, Lawrence D. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulm Pharmacol Ther 2010, 23:165-171. 10.1016/j.pupt.2010.01.003, 20080201.
-
(2010)
Pulm Pharmacol Ther
, vol.23
, pp. 165-171
-
-
Barnes, P.J.1
Pocock, S.J.2
Magnussen, H.3
Iqbal, A.4
Kramer, B.5
Higgins, M.6
Lawrence, D.7
-
6
-
-
77954102187
-
Once-daily indacaterol provides effective bronchodilation over 1 year of treatment in patients with chronic obstructive pulmonary disease (COPD)
-
Rennard SI, Chapman KR, Luthra A, Swales J, Lassen C, Owen R, Kramer B. Once-daily indacaterol provides effective bronchodilation over 1 year of treatment in patients with chronic obstructive pulmonary disease (COPD). Chest 2009, 136:4S.
-
(2009)
Chest
, vol.136
-
-
Rennard, S.I.1
Chapman, K.R.2
Luthra, A.3
Swales, J.4
Lassen, C.5
Owen, R.6
Kramer, B.7
-
7
-
-
36248961734
-
Innovative approaches for designing and analyzing adaptive dose-ranging trials
-
10.1080/10543400701643848, 18027208
-
Bornkamp B, Bretz F, Dmitrienko A, Enas G, Gaydos B, Hsu CH, Konig F, Krams M, Liu Q, Neuenschwander B, Parke T, Pinheiro J, Roy A, Sax R, Shen F. Innovative approaches for designing and analyzing adaptive dose-ranging trials. J Biopharm Stat 2007, 17:965-995. 10.1080/10543400701643848, 18027208.
-
(2007)
J Biopharm Stat
, vol.17
, pp. 965-995
-
-
Bornkamp, B.1
Bretz, F.2
Dmitrienko, A.3
Enas, G.4
Gaydos, B.5
Hsu, C.H.6
Konig, F.7
Krams, M.8
Liu, Q.9
Neuenschwander, B.10
Parke, T.11
Pinheiro, J.12
Roy, A.13
Sax, R.14
Shen, F.15
-
8
-
-
0036014549
-
Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial
-
10.1183/09031936.02.00240902, 12030736
-
Aalbers R, Ayres J, Backer V, Decramer M, Lier PA, Magyar P, Malolepszy J, Ruffin R, Sybrecht GW. Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Eur Respir J 2002, 19:936-943. 10.1183/09031936.02.00240902, 12030736.
-
(2002)
Eur Respir J
, vol.19
, pp. 936-943
-
-
Aalbers, R.1
Ayres, J.2
Backer, V.3
Decramer, M.4
Lier, P.A.5
Magyar, P.6
Malolepszy, J.7
Ruffin, R.8
Sybrecht, G.W.9
-
9
-
-
0029031264
-
Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study
-
10.1016/0954-6111(95)90008-X, 7638371
-
Cazzola M, Matera MG, Santangelo G, Vinciguerra A, Rossi F, D'Amato G. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir Med 1995, 89:357-362. 10.1016/0954-6111(95)90008-X, 7638371.
-
(1995)
Respir Med
, vol.89
, pp. 357-362
-
-
Cazzola, M.1
Matera, M.G.2
Santangelo, G.3
Vinciguerra, A.4
Rossi, F.5
D'Amato, G.6
-
10
-
-
0028814552
-
Comparative dose-response study of three anticholinergic agents and fenoterol using a metered dose inhaler in patients with chronic obstructive pulmonary disease
-
10.1136/thx.50.1.62, 473711, 7886652
-
Ikeda A, Nishimura K, Koyama H, Izumi T. Comparative dose-response study of three anticholinergic agents and fenoterol using a metered dose inhaler in patients with chronic obstructive pulmonary disease. Thorax 1995, 50:62-66. 10.1136/thx.50.1.62, 473711, 7886652.
-
(1995)
Thorax
, vol.50
, pp. 62-66
-
-
Ikeda, A.1
Nishimura, K.2
Koyama, H.3
Izumi, T.4
-
11
-
-
0034099036
-
Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease
-
Littner MR, Ilowite JS, Tashkin DP, Friedman M, Serby CW, Menjoge SS, Witek TJ. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000, 161:1136-1142.
-
(2000)
Am J Respir Crit Care Med
, vol.161
, pp. 1136-1142
-
-
Littner, M.R.1
Ilowite, J.S.2
Tashkin, D.P.3
Friedman, M.4
Serby, C.W.5
Menjoge, S.S.6
Witek, T.J.7
-
12
-
-
43549104866
-
Systemic and bronchodilator effects of inhaled rac-formoterol in subjects with chronic obstructive pulmonary disease: a dose-response study
-
10.1111/j.1365-2125.2007.03081.x, 2485218, 18394012
-
Whale CI, Sovani MP, Mortimer KJ, Harrison TW, Tattersfield AE. Systemic and bronchodilator effects of inhaled rac-formoterol in subjects with chronic obstructive pulmonary disease: a dose-response study. Br J Clin Pharmacol 2008, 65:841-847. 10.1111/j.1365-2125.2007.03081.x, 2485218, 18394012.
-
(2008)
Br J Clin Pharmacol
, vol.65
, pp. 841-847
-
-
Whale, C.I.1
Sovani, M.P.2
Mortimer, K.J.3
Harrison, T.W.4
Tattersfield, A.E.5
-
13
-
-
64249171524
-
24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterol
-
10.1185/03007990802675096, 19192991
-
Bauwens O, Ninane V, Van de Maele B, Firth R, Dong F, Owen R, Higgins M. 24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterol. Curr Med Res Opin 2009, 25:463-470. 10.1185/03007990802675096, 19192991.
-
(2009)
Curr Med Res Opin
, vol.25
, pp. 463-470
-
-
Bauwens, O.1
Ninane, V.2
Van de Maele, B.3
Firth, R.4
Dong, F.5
Owen, R.6
Higgins, M.7
-
14
-
-
44749085093
-
A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison
-
10.1016/j.rmed.2008.02.001, 18479895
-
Rennard S, Bantje T, Centanni S, Chanez P, Chuchalin A, D'Urzo A, Kornmann O, Perry S, Jack D, Owen R, Higgins M. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med 2008, 102:1033-1044. 10.1016/j.rmed.2008.02.001, 18479895.
-
(2008)
Respir Med
, vol.102
, pp. 1033-1044
-
-
Rennard, S.1
Bantje, T.2
Centanni, S.3
Chanez, P.4
Chuchalin, A.5
D'Urzo, A.6
Kornmann, O.7
Perry, S.8
Jack, D.9
Owen, R.10
Higgins, M.11
-
15
-
-
40649117704
-
Outcomes for COPD pharmacological trials: from lung function to biomarkers
-
10.1183/09031936.00099306, 18238951
-
Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, Brusasco V, Burge PS, Calverley PM, Celli BR, Jones PW, Mahler DA, Make B, Miravitlles M, Page CP, Palange P, Parr D, Pistolesi M, Rennard SI, Rutten-van Molken MP, Stockley R, Sullivan SD, Wedzicha JA, Wouters EF. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008, 31:416-469. 10.1183/09031936.00099306, 18238951.
-
(2008)
Eur Respir J
, vol.31
, pp. 416-469
-
-
Cazzola, M.1
MacNee, W.2
Martinez, F.J.3
Rabe, K.F.4
Franciosi, L.G.5
Barnes, P.J.6
Brusasco, V.7
Burge, P.S.8
Calverley, P.M.9
Celli, B.R.10
Jones, P.W.11
Mahler, D.A.12
Make, B.13
Miravitlles, M.14
Page, C.P.15
Palange, P.16
Parr, D.17
Pistolesi, M.18
Rennard, S.I.19
Rutten-van Molken, M.P.20
Stockley, R.21
Sullivan, S.D.22
Wedzicha, J.A.23
Wouters, E.F.24
more..
-
18
-
-
0003736032
-
Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease
-
GOLD
-
GOLD Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. 2007, GOLD.
-
(2007)
-
-
-
19
-
-
0003736032
-
Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease
-
GOLD
-
GOLD Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. 2009, GOLD.
-
(2009)
-
-
-
20
-
-
22744439763
-
Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease
-
10.1517/13543784.14.7.775, 16022567
-
Cazzola M, Matera MG, Lotvall J. Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2005, 14:775-783. 10.1517/13543784.14.7.775, 16022567.
-
(2005)
Expert Opin Investig Drugs
, vol.14
, pp. 775-783
-
-
Cazzola, M.1
Matera, M.G.2
Lotvall, J.3
-
21
-
-
28244497329
-
Measuring the effects of COPD on the patient
-
Jones P, Lareau S, Mahler DA. Measuring the effects of COPD on the patient. Respir Med 2005, 99:S11-S18.
-
(2005)
Respir Med
, vol.99
-
-
Jones, P.1
Lareau, S.2
Mahler, D.A.3
-
22
-
-
0021256105
-
The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes
-
10.1378/chest.85.6.751, 6723384
-
Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984, 85:751-758. 10.1378/chest.85.6.751, 6723384.
-
(1984)
Chest
, vol.85
, pp. 751-758
-
-
Mahler, D.A.1
Weinberg, D.H.2
Wells, C.K.3
Feinstein, A.R.4
-
23
-
-
84857983364
-
Correlating changes in lung function with patient reported outcomes in COPD (abstract)
-
Jones PW, Donohue J, Nedelman J, Pinault G, Pascoe S. Correlating changes in lung function with patient reported outcomes in COPD (abstract). Thorax 2010, 65:A141.
-
(2010)
Thorax
, vol.65
-
-
Jones, P.W.1
Donohue, J.2
Nedelman, J.3
Pinault, G.4
Pascoe, S.5
|